Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00387582 · ClinicalTrials.gov registry record · Phase 2

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

A Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Rocky Mountain Retina Consultants.

Completed
Registry status
Phase 2
Development phase
49
Enrollment target
1
Study location

NCT00387582: Completed Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Rocky Mountain Retina Consultants.

NCT00387582 is a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy that has completed, run by Rocky Mountain Retina Consultants. The registered enrollment target is 49 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00387582, a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, has completed, sponsored by Rocky Mountain Retina Consultants.

COMPLETED
Registry status
Phase 2
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab (Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.

Interventions

  • DRUG Ranibizumab (Lucentis)
  • PROCEDURE Argon Laser

Study Locations (1)

Utah

  • Rocky Mountain Retina Consultants - Salt Lake City

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2006-07
Est. Completion 2009-02
Phase Phase 2

What the finished NCT00387582 record still lists

NCT00387582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab (Lucentis) is the first listed.

NCT00387582 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT00387582 about?

NCT00387582 is a clinical study titled "Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema". This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab (Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.

What is the current status of trial NCT00387582?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2006-07. Estimated completion is 2009-02.

What conditions does trial NCT00387582 study?

This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy.

What interventions are being tested in trial NCT00387582?

The interventions under investigation include: Ranibizumab (Lucentis) (DRUG), Argon Laser (PROCEDURE).

Who is sponsoring clinical trial NCT00387582?

This trial is sponsored by Rocky Mountain Retina Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00387582 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Macular Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00387582's enrollment target sits among peer trials

49 38th of 63 higher than 26 of 63 other Diabetic Macular Edema trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00387582, the US trial registry maintained by the National Library of Medicine. NCT00387582 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.